Cupressus arizonica pollen allergy immunotherapy - ALK-Abello

Drug Profile

Cupressus arizonica pollen allergy immunotherapy - ALK-Abello

Alternative Names: Arizona cypress pollen allergy immunotherapy; AVANZ Cupressus; Cupressus pollen allergy immunotherapy; Polen de Cupressus arizonica immunotherapy

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinoconjunctivitis

Most Recent Events

  • 25 Nov 2016 Launched for Allergic rhinoconjunctivitis in Spain before November 2016 (SC) (ALK-Abello email communication)
  • 01 Nov 2014 ALK-Abello completes a phase II trial in Allergic rhinoconjunctivitis in Spain (NCT02069535)
  • 28 Aug 2014 CTP push (NCT02069535)- now recruiting, removed EudraCT2013-001728-20 from profile as this record no longer contains info related to Cupressus immunotherapy (RDI 39488), changed phase date to match NCT02069535 & changed phase from II/III to II as per NCT and updated Eudra record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top